Researchers have developed a new compound, ZTA-261, that binds to thyroid hormone receptor beta (THR ). THR plays an important role in the regulation of lipid metabolism, which affects lipid levels in ...

This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in children. This recommendation statement was first published in ...

Please provide your email address to receive an email when new articles are posted on . The FDA extended its approval of alirocumab to treat a genetic lipid disorder in patients as young as 8 years.

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol and triglycerides in people with difficult-to-treat lipid disorders, ...

The American College of Cardiology (ACC) and the American Heart Association (AHA) released the 2026 ACC/AHA Guideline on the Management of Dyslipidemia. These guidelines introduce important updates in ...

A team of medics performing CPR and inserting an IV drip on a patient lying unconscious in a hospital bed. [iStockphoto] When 19-year-old *Jeffrey walked into Aga Khan Hospital after suffering a heart ...

Elevated lipoprotein(a) levels can slowly block the arteries, increasing the likelihood of cardiovascular disease. Since no treatment is currently available for this condition, it is essential to ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization in the European Union to Tryngolza (olezarsen; Ionis ...

Scientists at Nagoya University in Japan have made a significant breakthrough in treating lipid disorders. They have developed a new compound, ZTA-261, which selectively binds to the thyroid hormone ...